IRCT20200422047168N2.

Methods	Trial design: single‐blind RCT with 2 parallel arms Type of record: trial register entry Sample size: 60 Setting: inpatient Country: Iran Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: IRCT20200422047168N2 Date of registration: 30 May 2020
Participants	Inclusion criteria Aged > 18 years RT‐PCR test results for SARS‐CoV‐2 virus were positive after sampling (nasopharynx and oropharynx swab samples) Manifestations of virus pneumonia in CT scans of their lungs were quite obvious SpO2 saturation ≤ 93% Exclusion criteria History of renal failure Taking drugs that interfere with ivermectin People who have been admitted to other clinical trials
Interventions	Details of intervention Type and dose: ivermectin 0.15–0.2 mg/kg, single dose Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care including chloroquine, lopinavir/ritonavir (Kaletra) administered in both study arms
Outcomes	Primary study outcome Unclear from protocol, either mortality or participants discharged within 7 days Relevant review outcomes planned None Additional study outcomes Treatment period Duration of infection Duration of admission time Duration of ICU admission time Fever, blood SpO2 percentage, respiratory rate, heart rate, discharge situation within 7 days Use of non‐invasive respiratory methods within 7 days Use of invasive respiratory methods within 7 days
Notes	Reason for awaiting classification: study completed, but results not published yet Recruitment status: completed Prospective completion date: NR Date last update posted: 30 May 2020 Sponsor/funding: Ahvaz University of Medical Sciences